With decades of experience in management and consulting within the clinical research and aviation industries across Bolivia, Hong Kong, and the US, Dr. Keith Tong exemplifies a unique blend of engineering expertise, business acumen, and nonprofit leadership.
Dermatologists see melanoma as a personal challenge. $ENZC #ENZC is here to support them with a new, effective treatment option. #Dermatology#SupportSystem
Estimates are that The U.S. melanoma market is anticipated to reach $5.73 Billion by 2030 and the global market for melanoma treatment was estimated to reach $8.5 billion by 2030
Every year, more than 9,000 people die from melanoma in the US and 57,000 worldwide. $ENZC $ENZC (with Bulgarian Academy of Sciences) goal is to make this number obsolete. #NoMoreDeaths#MelanomaMission
Every year, more than 9,000 people die from melanoma in the US and 57,000 worldwide. $ENZC $ENZC (with Bulgarian Academy of Sciences) goal is to make this number obsolete. #NoMoreDeaths#MelanomaMission
Dr. Keith Tong is an integral part of the Sagaliam and $ENZC $ENZC story. He holds a Ph.D. in Electrical, Electronics, and Computing Engineering with a focus on Physics from the University of Edinburgh, as well as an MBA from the University of Hong Kong
Combination therapies are changing how we treat melanoma. $ENZC $ENZC (with Bulgarian Academy of Sciences) drug is designed to complement existing treatments for better efficacy. #CombinationTherapy#MelanomaProgress"
The latest press release demonstrates our commitment to a new and brighter future for $ENZC #ENZC. We expect to be announcing additional info on future acquisitions imminently.
$ENZC #ENZC definitely suffers from misstatements made by previous management team. We urge investors to disregard those who drove ENZC into a bad place, understanding that new ENZC is working hard to turn things around.
$ENZC #ENZC has changed its direction -it's different from the old ENZC. The new entity has distinct upside ... The New ENZC is NOT party to any litigation at this point. All the noise in the market is from transactions originating with the old management.
it appears that Savov has falsely claimed that $ENZC #ENZC has been named in the SEC litigation. Please know that this statement is totally false and, in our opinion, more sour grapes from losing his cases against the company and its predecessor Immunotech Laboratories, Inc.
We $ENZC $ENZC are also spending time educating the market on the truth and pointing out the inaccuracies of those who are trying to (sadly) steal our technology.
The new direction for $ENZC #ENZC is focused on two areas 1) commercialization of our licensed cancer treatment with support through our alliances and partnerships 2) increasing our industry collaboration.